Recalled Medicines & supplements – Current GIS Alerts 2026
Found 713 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Tadalafil Aristo
It cannot be excluded that keeping this medicinal product on the market may pose a risk to patient health, due to identified non-compliances with Good Manufacturing Practice at one manufacturer and the possibility of a quality defect. Potential effects: risk to patient health, possible lack of efficacy or other treatment complications.
Tadalafil Aristo
Non-compliance with Good Manufacturing Practice was found at one of the manufacturers, resulting in suspension of the GMP certificate, so it cannot be excluded that keeping the product on the market may pose a risk to patient health. Potential effects: possible risk to patient health, including lack of treatment efficacy or unpredictable adverse effects.
Structum
Out-of-specification results were found for the TAMC parameter (total aerobic microbial count) and the presence or probability of occurrence of Bacillus cereus was demonstrated. Potential effects: bacterial infection, gastrointestinal symptoms, possible intoxication.
Angusta
Given that the cause of the out-of-specification result for an unknown impurity and its impact on the product quality and safety of use are currently unknown, it cannot be ruled out that keeping this product on the market may pose a threat to patient health. Potential effects: threat to patient health.
Lactulose-MIP
A risk of microbiological contamination of the active substance used to produce the syrup was identified, resulting in a quality defect of the product and a potential direct threat to patients’ health or life. Potential effects: infection, complications, health risk.
Lactulose-MIP
A risk of microbiological contamination of the active substance used to manufacture the medicinal product was reported, creating a potential threat to patients' health. Potential effects: infections, complications, lack of treatment safety.
Sumilar HCT
Capsules with an abnormal appearance and colour were identified inside the blister, which constitutes a suspected quality defect of the medicinal product and a potential risk to patients’ health or life. Potential effects: lack of certainty regarding treatment efficacy and safety.
Hemkortin-HC
An error was found in the printed strength of the active substances on the immediate packaging, affecting some tubes in batch D0222, which may lead to incorrect use of the medicine. Potential effects: improper dosing, risk of adverse reactions or lack of treatment efficacy.
Accupro 40
The letter concerned a request for a decision to withdraw the specified batches of medicinal products from the market due to the presence of contamination (N-nitroso-quinapril) above the permitted daily intake limit. Potential effects: possible carcinogenic effects, organ damage, complications of hypertension therapy.
Accupro 10
detection of contamination (N-nitroso-quinapril) above the acceptable daily intake limit. Potential effects: possible carcinogenic effect and increased risk of adverse reactions.
Accupro 5
due to the detected presence of contamination (N-nitroso-quinapril) above the acceptable daily intake limit. Potential effects: possible carcinogenic or toxic effects and a health risk for patients.
Vigantol
Suspected quality defect of the medicinal product resulting from the use of an excipient linked to a batch with an out-of-specification active substance content, which may lead to incorrect dosing of vitamin D. Potential effects: lack of efficacy or adverse effects related to overdose.
Accupro 20
the presence of the impurity (N-nitroso-quinapril) above the acceptable daily intake limit. Potential effects: increased risk of toxicity and carcinogenic effects, especially during long-term use.
NETSPOT
A quality defect of the NETSPOT product was identified – stability test results showed the content of the active substance DOTATATE close to the lower limit of the specification, meaning that established quality requirements are not met. Potential effects: lack of diagnostic efficacy, risk of delayed disease diagnosis.
Biotrakson
An out-of-specification result for the endotoxin parameter was found in archival samples of an injectable product, which may pose a real and highly probable risk to patients’ health or life. Potential effects: poisoning, severe systemic reactions, septic complications.
GLICERYNA 85 %
Out-of-specification results were found for the sugars parameter in the pharmaceutical raw material GLYCERIN 85%, used for preparing magistral medicines, creating a potential risk to patients' health or life. Potential effects: lack of quality and safety of compounded medicines, possible complications.
Atorvox
An error on the outer packaging (simultaneous strength markings 40 mg and 20 mg) may lead to incorrect dispensing from the pharmacy and improper dosing by patients, which may pose a risk to life or health. Potential effects: improper statin dosing, cardiovascular complications or adverse reactions.
APAP Intense
It was found that the medicinal product sample does not meet the specification in the product documentation regarding the appearance parameter, which constitutes a quality defect. Potential effects: possible reduced treatment efficacy or unpredictable drug action.
Vigantol
An out-of-specification result was found during stability testing regarding the active substance content parameter. Potential effects: lack of efficacy or overdose of vitamin D, possible health disorders.
Appetite Blocker
Ethylene oxide detected in the raw material used to produce the dietary supplement. Potential effects: toxic effects, no safe level of intake, risk of long-term health effects.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.